Skip to main content
Journal cover image

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.

Publication ,  Journal Article
Khalil, MA; Qiao, W; Carlson, P; George, B; Javle, M; Overman, M; Varadhachary, G; Wolff, RA; Abbruzzese, JL; Fogelman, DR
Published in: Invest New Drugs
October 2013

Metastatic pancreatic cancer carries a poor prognosis, with median survival on the order of several months. There is evidence that combining gemcitabine with either erlotinib or cisplatin may be superior to single agent gemcitabine in patients with good performance (PS 0-1). We retrospectively compared outcomes of patients treated with either the three drug regimen of gemcitabine, cisplatin, and erlotinib (GCE) or the doublet of gemcitabine and cisplatin (GC) in order to assess the potential benefit of erlotinib. We also evaluated the role of erlotinib among smokers and non-smokers. We retrospectively analyzed 145 patients who presented between 2006 and 2009 with previously untreated metastatic pancreatic cancer initially treated at the M.D. Anderson cancer center with either GC or GCE. Information on tumor characteristics and overall survival time (OS) was collected by medical record review. Kaplan-Meier curves were used to estimate OS. Log rank tests were used to compare OS between groups. The Cox proportional hazards regression model was used to evaluate the ability of patient prognostic variables or treatment group to predict OS. A total of 71 patients were treated with GC, while 74 were treated with GCE. Cox analyses found no significant difference in overall survival (median 5.5 vs. 8.0 months, respectively, p-value=0.1). Small sampling numbers may have contributed to this result. One year survival was 23 % in the GCE group and 13 % in the GC group. Patients with poor performance status (PS=2-3) had worse survival as compared to patients with better performance status (PS=0-1, p=0.001). As in earlier studies, patients treated with more lines of therapy tended to have better survival (p <0.0001), and CA19-9 was found to be a significant predictor for OS (p=0.001). No statistical evidence of a survival difference was found between smokers and non-smokers in both treatment groups (p=0.72). In conclusion, though there was a trend towards improved survival with the addition of erlotinib to gemcitabine and cisplatin, this does not reach statistical significance.

Duke Scholars

Published In

Invest New Drugs

DOI

EISSN

1573-0646

Publication Date

October 2013

Volume

31

Issue

5

Start / End Page

1375 / 1383

Location

United States

Related Subject Headings

  • Quinazolines
  • Protein Kinase Inhibitors
  • Peritoneal Neoplasms
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Liver Neoplasms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khalil, M. A., Qiao, W., Carlson, P., George, B., Javle, M., Overman, M., … Fogelman, D. R. (2013). The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs, 31(5), 1375–1383. https://doi.org/10.1007/s10637-013-9967-2
Khalil, Mohamed A., Wei Qiao, Peter Carlson, Binsah George, Milind Javle, Michael Overman, Gauri Varadhachary, Robert A. Wolff, James L. Abbruzzese, and David R. Fogelman. “The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.Invest New Drugs 31, no. 5 (October 2013): 1375–83. https://doi.org/10.1007/s10637-013-9967-2.
Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, et al. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct;31(5):1375–83.
Khalil, Mohamed A., et al. “The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.Invest New Drugs, vol. 31, no. 5, Oct. 2013, pp. 1375–83. Pubmed, doi:10.1007/s10637-013-9967-2.
Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct;31(5):1375–1383.
Journal cover image

Published In

Invest New Drugs

DOI

EISSN

1573-0646

Publication Date

October 2013

Volume

31

Issue

5

Start / End Page

1375 / 1383

Location

United States

Related Subject Headings

  • Quinazolines
  • Protein Kinase Inhibitors
  • Peritoneal Neoplasms
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Liver Neoplasms